Johnson & Johnson (JNJ)

NYQ – Real Time Price. Currency in USD

253.91

+5.30 (2.13%)

At close: Oct 14, 2026, 4:00 PM EDT

258.80

+4.89 (1.93%)

Pre-market: Oct 15, 2026, 7:13 AM EDT

14.10.2026

Johnson & Johnson Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Johnson & Johnson (JNJ)

China pricing and European budget cuts were cited among the pressures behind a MedTech consensus miss that sent Johnson & Johnson shares lower. JNJ investors with losses can request a review.

14.10.2026

These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results

Johnson & Johnson (NYSE:JNJ) on Tuesday reported upbeat third-quarter results and raised its full-year guidance.

14.10.2026

Stock of the Day: Is this the Bottom for Johnson & Johnson?

Trading in Johnson & Johnson (NYSE:JNJ) is quiet Wednesday. The shares dropped by almost 6% yesterday after the company reported its earnings.

14.10.2026

JNJ Q3 Earnings Call Highlights Growth Outlook and MedTech Challenges

Johnson & Johnson raises its 2026 sales and earnings outlook as strong pharmaceutical growth offsets MedTech challenges, while 2027 dilution clouds the outlook.

14.10.2026

J&J Beat and Raised. The Stock Fell Anyway.

Johnson and Johnson crushed earnings, raised guidance, and still watched its stock crater nearly 6% in a single session. Understanding what spooked investors reveals whether Tuesday's selloff is a trap or a warning.

14.10.2026

Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying

Every big pharma company eventually watches its best-selling drug go generic, yet some keep raising their dividends anyway.

14.10.2026

Johnson & Johnson shares SLIDE nearly 6% despite stronger full-year forecast

Johnson & Johnson executive vice president and CFO Joe Wolk discusses the company's third-quarter earnings, raising its full-year guidance, a potential spinoff of its DePuy Synthes orthopedics unit, and more, on 'The Claman Countdown.'

Videos

14.10.2026

Negative

Johnson & Johnson shares SLIDE nearly 6% despite stronger full-year forecast

13.10.2026

Positive

J&J raises its forecast again. CFO Joe Wolk on what's driving it

13.10.2026

Negative

Johnson & Johnson shares fall following earnings

13.10.2026

Neutral

Tuesday's First Moves: WFC Mixed Earnings, JNJ Beat & Raise, DPZ Slides

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
JNJ	UBS	Buy	undefined >> $320	September 2nd 2026

Press releases

14.10.2026

Johnson & Johnson Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Johnson & Johnson (JNJ)

China pricing and European budget cuts were cited among the pressures behind a MedTech consensus miss that sent Johnson & Johnson shares lower. JNJ investors with losses can request a review.

13.10.2026

Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2026 of $1.34 per share on the company's common stock. The dividend is payable on December 8, 2026 to shareholders of record at the close of business on November 24, 2026. The ex-dividend date is November 24, 2026. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare.

13.10.2026

Johnson & Johnson reports Q3 2026 results, raises 2026 guidance

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2026. “Johnson & Johnson's strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio,” said Joaquin Duato, Chairman and Chief Executive Officer. “In the third quarter, we advanced breakthroughs that will redefine care for patients, from delivering one of our most transformative MedTech innovations with OTTAVA to r.

12.10.2026

New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups

New prespecified analyses showed consistent findings across clinically important and difficult to treat subgroups, including patients with prior biologic exposure Findings build on first positive results where TREMFYA achieved combined fistula remission rates of up to 28% across dosing groups Results come from the first dedicated Phase 3 randomized, placebo-controlled trial in adults managing Crohn's disease with perianal fistula in more than 20 years SPRING HOUSE, Pa., Oct. 12, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new Phase 3 data showing consistent combined fistula remission outcomes with TREMFYA® (guselkumab) across clinically important subgroups of adults with Crohn's disease with perianal fistula.1 The prespecified subgroup analyses from the FUZION study are being presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting and build on previously reported Week 24 results from the overall study population.

Johnson & Johnson (JNJ)

Get all premium features to the best stock analysis tool

Finranks

Contact us

Follow us

Johnson & Johnson (JNJ)

Johnson & Johnson Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Johnson & Johnson (JNJ)

These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results

Stock of the Day: Is this the Bottom for Johnson & Johnson?

JNJ Q3 Earnings Call Highlights Growth Outlook and MedTech Challenges

J&J Beat and Raised. The Stock Fell Anyway.

Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying